Medicare is opening access to popular GLP-1 weight-loss drugs for millions of older Americans starting July 1, 2026, marking a significant shift in federal health coverage.
The initiative, announced by the Centers for Medicare and Medicaid Services, is a short-term pilot program known as the Medicare GLP-1 Bridge, running through December 31, 2027.
Current federal law prohibits Medicare Part D from covering medications prescribed purely for weight loss, making this pilot program a temporary workaround to address that gap.
Through the program, eligible Medicare recipients can access blockbuster anti-obesity medications like Wegovy and Zepbound for a fixed $50 monthly copay.
CMS negotiated directly with pharmaceutical manufacturers to secure a net price of $245 per month for these drugs, passing the savings on to patients enrolled in the program.
More than 56 million Americans have Medicare Part D, and if roughly 40 percent of them have obesity, as statistics suggest, approximately 22 million people could potentially qualify.
To be eligible, beneficiaries must meet specific BMI thresholds combined with certain health conditions, including prediabetes, high blood pressure, chronic kidney disease, heart failure, or a previous heart attack or stroke.
CMS has appointed Humana as the centralized processor to handle all prior authorizations and claims under the program, replacing the standard Part D plan process.
Doctors do not need to be enrolled as Medicare providers to write prescriptions or submit prior authorization requests, which is intended to broaden patient access quickly.
Despite the affordability gains, KFF’s Juliette Cubanski cautioned that “$50 a month sounds like a great deal compared to paying the discounted prices through TrumpRx and these other direct-to-consumer options, but it’s a lot of money for somebody who’s living on a $750-a-month Social Security check.”
Dr. Harlan Krumholz, a cardiologist and professor at the Yale School of Medicine, expressed enthusiasm but also urged caution regarding older patient populations specifically.
“I’m tremendously excited that we’re addressing the access and affordability issues for people so that they have that option,” Krumholz said, while noting important limitations in the existing research.
He added that “the older you are, the less evidence there is from any trial about you, because most of these trials haven’t really enrolled people over 70 or 80, so we need to continue to learn and see how this works.”
A major concern among providers is what happens when the program’s pre-defined end date arrives and patients who depend on the drugs lose access to affordable coverage.
John Batsis, a University of North Carolina School of Medicine obesity specialist, warned that discontinuation could carry serious physical consequences for older users of these medications.
“Not only will weight come back, comorbidities will come back, and we know from lifestyle studies, when you gain it back, you’re gaining more fat than muscle,” Batsis said.
GLP-1 drugs work best when taken continuously, and stopping them abruptly could leave older patients with reduced muscle mass, potentially increasing their risk of frailty and other complications.
